INOVIO is powering a new way forward in DNA medicines to meet urgent global health needs.

INOVIO’s DNA medicines are designed to activate the immune system in vivo to generate robust T cell and antibody responses, protect against pathogens, and break immune tolerance for tumors.

INOVIO’s modern platform is like no other DNA or mRNA technology, pairing rapid design with groundbreaking delivery. First, we select an appropriate target, such as a tumor-associated antigen or viral antigen. Next, we create a consensus sequence for the target antigen, which is modified to activate the desired immune response. Once the sequence is complete, we insert it into a DNA plasmid, and the therapy is ready for delivery.

Our CELLECTRA® smart device delivers these optimized DNA plasmids directly into the cell, overcoming a key limitation of other DNA or mRNA approaches.

Once inside the cell, the DNA plasmids enable the cell to produce the consensus antigen. The antigen is processed properly in the cell and triggers the desired T cell and antibody-mediated immune responses.

With their rapid design and manufacture, and potential for efficacy, versatility, flexibility, and tolerability as demonstrated in clinical trials involving more than 2,000 patients, INOVIO’s DNA medicines are poised to be a foundational approach in the global fight against HPV-associated diseases, cancer, and infectious diseases.

INOVIO…Powering DNA Medicines.

Learn more at INOVIO.com.

свернуть